* Meta-terms correspond to biological or medical specialty concerned with one or more keywords (or keywords hierarchies), qualifiers, or resource types. Other terms also benefit from this structure, when the topic warrants it, eg education. See the list.

Doc'CISMeF search for this specility :


Preferred Label : oncology;

True Meta (CISMeF) : O;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3610362/fr/vyloy-zolbetuximab-adenocarcinome-gastrique-et-de-la-jonction-oesogastrique
2025
false
false
false
France
zolbetuximab
Gastroesophageal Junction Adenocarcinoma
insurance, health, reimbursement
treatment outcome
evaluation of the transparency committee
zolbetuximab
cardioesophageal junction
esophagogastric junction
stomach, nos
adenocarcinoma
zolbetuximab

---
https://www.has-sante.fr/jcms/p_3610014/fr/darzalex-daratumumab-myelome-multiple
2025
false
false
false
France
antineoplastic combined chemotherapy protocols
treatment outcome
insurance, health, reimbursement
Bortezomib/Daratumumab/Dexamethasone/Lenalidomide Regimen
Bortezomib
dexamethasone
Lenalidomide
antineoplastic agents
daratumumab
hematopoietic stem cell transplantation
transplantation, autologous
evaluation of the transparency committee
multiple myeloma
daratumumab

---
https://www.has-sante.fr/jcms/p_3610371/fr/tecentriq-atezolizumab-cancer-du-poumon
2025
France
evaluation of the transparency committee
neoplasm, malignant
Tecentriq
atezolizumab
lung cancer
atezolizumab
lung neoplasms

---
https://www.sfed.org/wp-content/uploads/2025/06/Prise-en-charge-endoscopique-Polypose-Adenomateuse-Familiale-reco-2024-juin-2025.pdf
2025
France
practice guideline
gene, nos
patient care management
health planning guidelines
familial multiple polyposis syndrome
adaptation, nos
adenomatous polyposis coli
genes, apc
endoscope, nos
endoscopy, nos
endoscopes
endoscopy
rehabilitation
habilitation

---
https://ansm.sante.fr/tableau-marr/bcg-bacille-de-calmette-guerin-vivant-attenue
2025
false
false
false
France
French
risk management
LIVE BCG BACILLI (BACILLUS CALMETTE-GUERIN), BRASILIAN MOREAU SUBSTRAIN
urinary bladder neoplasms
administration, intravesical
popular works
drug information
BCG vaccine
mycobacterium infections
Infection caused by Mycobacterium tuberculosis (disorder)
bcg vaccine

---
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015124.pub2/full/fr
2025
United Kingdom
review of literature
french abstract
neoplasm, malignant
Cancer Survivors
Prognostic Factors
postman
work
breast neoplasms
prognosis
return to work
occupation, nos
breast cancer

---
https://www.has-sante.fr/jcms/p_3632479/fr/rybrevant-amivantamab-lazcluze-lazertinib-en-association-cbnpc
2025
false
false
false
France
lazertinib
amivantamab
Amivantamab/Lazertinib Regimen
evaluation of the transparency committee
lazertinib
antineoplastic combined chemotherapy protocols
carcinoma, non-small-cell lung
amivantamab

---
https://www.cbip.be/fr/articles/4553?folia=4552
2025
false
false
false
Belgium
French
drug information
journal article
neoplasms
proton pump inhibitors
survival analysis
antineoplastic agents
survival
cohort studies
Reduced drug efficacy
antineoplastic agents
drug interactions

---
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015140.pub2/full/fr
2025
United Kingdom
review of literature
french abstract
EGF Receptors
mutation
epidermal growth factor-urogastrone receptor site
due to
adjuvant, nos
neoplasm, malignant
epidermal growth factor
neoplasm staging
persons
carcinoma, non-small-cell lung
disease
"u" lymphocyte
small cell lung carcinoma
excision, nos
receptors, growth factor
tyrosine
receptor Protein-Tyrosine kinases
Tyrosine Kinase Inhibitors

---
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015520/full/fr
2025
United Kingdom
review of literature
french abstract
neoplasms
persons
cancer
disease
fatigue
yoga
neoplasm, malignant
fatigue

---
https://www.assurance-maladie.ameli.fr/etudes-et-donnees/incidence-nouvelles-exonerations-ald-tumeur-maligne
2025
France
scientific and technical information
due to
adrenoleukodystrophy
incidence
neoplasms
fructose-bisphosphate aldolase
chronic disease
neoplasms by site

---
https://www.immunite-cancer.fr/
false
false
false
false
false
France
periodicals
immunity
immunotherapy
medical oncology
neoplasms

---
https://www.calameo.com/onco-occitanie/read/0071780926f9da30c68d6
2025
France
guideline
drug, nos
home care services, hospital-based
drug therapy
cancer
neoplasms
neoplasm, malignant

---
https://www.has-sante.fr/jcms/p_3575020/fr/tecartus-brexucabtagene-autoleucel-lymphome-a-cellules-du-manteau-lcm
2025
false
false
false
France
evaluation of the transparency committee
antigens, CD19
"u" lymphocyte
brexucabtagene autoleucel
brexucabtagene autoleucel
cells

---
https://www.has-sante.fr/jcms/p_3576072/fr/padcev-enfortumab-vedotin-carcinome-urothelial
2025
false
false
false
France
Urothelial Carcinoma
evaluation of the transparency committee
enfortumab vedotin
carcinoma
enfortumab vedotin

---
https://www.has-sante.fr/jcms/p_3574834/fr/tibsovo-ivosidenib-cancer-voies-biliaires
2025
false
false
false
France
locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation
evaluation of the transparency committee
ivosidenib
ivosidenib
biliary tract, nos
neoplasm, malignant
Tibsovo
biliary tract neoplasms
biliary tract cancer

---
https://www.has-sante.fr/jcms/p_3576306/fr/imfinzi-durvalumab-et-lynparza-olaparib-en-association-cancer-de-l-endometre
2025
false
false
false
France
evaluation of the transparency committee
olaparib
cancer
Imfinzi
endometrial neoplasms
durvalumab
Lynparza
endometrium
neoplasm, malignant
olaparib
association
olaparib
durvalumab
Endomet

---
https://www.has-sante.fr/jcms/p_3576557/fr/vyloy-zolbetuximab-adenocarcinome-gastrique-et-de-la-jonction-oesogastrique
2025
false
false
false
France
antineoplastic combined chemotherapy protocols
treatment outcome
insurance, health, reimbursement
adult
Fluoropyrimidine
platinum salt, nos
Gastric Adenocarcinoma
stomach neoplasms
Gastroesophageal Junction Adenocarcinoma
esophageal neoplasms
HER2/Neu Negative
CLDN18.2 Positive
infusions, intravenous
zolbetuximab
evaluation of the transparency committee
zolbetuximab
adenocarcinoma

---
https://www.has-sante.fr/jcms/p_3576262/fr/jakavi-ruxolitinib-maladie-du-greffon-pediatrie
2025
false
false
false
France
administration, oral
pharmaceutical solutions
graft vs host disease
child
ruxolitinib
Janus Kinase Inhibitors
evaluation of the transparency committee
ruxolitinib

---
https://ansm.sante.fr/tableau-marr/denosumab
2025
false
false
false
France
French
risk management
Denosumab
patient education handout
drug information
osteonecrosis
Osteonecrosis of Jaw

---
https://www.has-sante.fr/jcms/p_3578491/fr/jemperli-dostarlimab-cancer-de-l-endometre
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
dostarlimab
antineoplastic combined chemotherapy protocols
Carboplatin/Dostarlimab/Paclitaxel Regimen
carboplatin
paclitaxel
Mismatch Repair Deficiency
High-Frequency Microsatellite Instability
adult
infusions, intravenous
antineoplastic agents
evaluation of the transparency committee
dostarlimab
endometrial neoplasms

---
https://www.has-sante.fr/jcms/p_3585759/fr/balversa-erdafitinib-carcinome-urothelial
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
erdafitinib
Product containing only erdafitinib in oral dose form (medicinal product form)
administration, oral
FGFR Inhibitor
receptors, fibroblast growth factor
adult
Unresectable Urothelial Carcinoma
Metastatic Urothelial Carcinoma
FGFR3 Gene Alteration Positive
receptor, fibroblast growth factor, type 3
Alteration of genetic material (finding)
evaluation of the transparency committee
Balversa
erdafitinib

---
https://www.has-sante.fr/jcms/p_3587072/fr/krazati-adagrasib-cancer-bronchique-non-a-petites-cellules
2025
false
false
false
France
adagrasib
KRAS NP_004976.2:p.G12C
KRAS Gene Mutation
evaluation of the transparency committee
adagrasib
carcinoma, non-small-cell lung

---
https://beh.santepubliquefrance.fr/beh/2025/3-4/2025_3-4_2.html
2025
France
journal article
early detection of cancer
cancer of the uterine cervix
screening for cancer
Program
period analysis
organization
french
uterine cervical neoplasms
demography
mass screening
malignant neoplasm cervix
cancer screening
insurance coverage
france

---
https://beh.santepubliquefrance.fr/beh/2025/3-4/2025_3-4_3.html
2025
France
journal article
cancer screening
breast neoplasms
mass screening
due to
screening for cancer
early detection of cancer
organization
french
Program
france
breast cancer

---
https://beh.santepubliquefrance.fr/beh/2025/3-4/2025_3-4_4.html
2025
France
journal article
malignant neoplasm colon/rectum
Respect
france
french
Colorectal Cancer
insurance coverage
colorectal neoplasms
early detection of cancer
screening for cancer
cancer screening
appraiser

---
https://www.ors-idf.org/nos-travaux/publications/mortalite-par-cancer-en-ile-de-france-evolutions-et-disparites-infradepartementales/
2025
France
technical report
mortality
french
cancer
neoplasms
neoplasm, malignant
france
paris

---
https://www.cancer.fr/catalogue-des-publications/traitements-de-1re-ligne-du-cbnpc-metastatique-sans-addiction-oncogenique-thesaurus
2025
France
practice guideline
Cloud Computing
oncogene
behavior, addictive
oncogenes
dependent drug abuse

---
https://www.has-sante.fr/jcms/p_3587094/fr/tibsovo-ivosidenib-cancer-voies-biliaires
2025
false
false
false
France
Locally Advanced Cholangiocarcinoma
treatment outcome
insurance, health, reimbursement
cholangiocarcinoma
ivosidenib
adult
Metastatic Cholangiocarcinoma
IDH1 NP_005887.2:p.R132X
locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation
administration, oral
antineoplastic agents
evaluation of the transparency committee
ivosidenib

---
https://www.has-sante.fr/jcms/p_3527462/fr/retsevmo-selpercatinib-cancer-de-la-thyroide
2025
false
false
false
France
adult
adolescent
treatment outcome
insurance, health, reimbursement
administration, oral
selpercatinib
advanced RET fusion-positive thyroid cancer
RET Fusion Positive
thyroid cancer, medullary
carcinoma, neuroendocrine
Advanced Thyroid Gland Medullary Carcinoma
RET Inhibitor
antineoplastic agents
evaluation of the transparency committee
selpercatinib
thyroid neoplasms

---
https://www.cancer.fr/catalogue-des-publications/conciliation-medicamenteuse-et-bilan-de-medication-des-patients-atteints-de-cancer
2025
France
technical report
medication reconciliation
neoplasm, malignant
neoplasms
cancer
has patient
patients
disease
albumin/globulin ratio
research report
drug, nos
Balance Sheet

---
https://www.cancer.fr/catalogue-des-publications/securisation-medicamenteuse-des-patients-traites-par-anticancereux-injectables-en-hopital-de-jour-d-oncologie-hematologie-referentiel-organisatio
https://www.cancer.fr/catalogue-des-publications/securisation-medicamenteuse-des-patients-traites-par-anticancereux-injectables-en-hopital-de-jour-d-oncologie-hematologie-synthese
2025
false
false
false
France
guideline
drug therapy
hospitals
administration of therapeutic substance, nos
antineoplastic agents
hematology
patients
day care center
hospital, nos
has patient
hospitalization
injections
Oncologists

---
https://www.cancer.fr/catalogue-des-publications/traitements-de-1re-ligne-du-cbnpc-metastatique-sans-addiction-oncogenique-synthese
https://www.cancer.fr/catalogue-des-publications/traitements-de-1re-ligne-du-cbnpc-metastatique-sans-addiction-oncogenique-thesaurus
2025
false
false
false
France
guideline
carcinoma, non-small-cell lung
behavior, addictive
oncogenes
oncogene
dependent drug abuse
fracture fixation
Cloud Computing

---
https://www.has-sante.fr/jcms/p_3590636/fr/imfinzi-durvalumab-cancer-de-l-endometre
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
Antineoplastic Agents, Immunological
durvalumab
antineoplastic combined chemotherapy protocols
Mismatch Repair Deficiency
adult
Advanced Endometrial Carcinoma
Recurrent Endometrial Carcinoma
neoplasm recurrence, local
infusions, intravenous
evaluation of the transparency committee
durvalumab
endometrial neoplasms

---
https://ansm.sante.fr/tableau-acces-derogatoire/avastin-r-25-mg-ml-solution-a-diluer-pour-perfusion
2025
false
false
false
France
French
Bevacizumab
drug information
guidelines for drug use
telangiectasia, hereditary hemorrhagic

---
https://www.has-sante.fr/jcms/p_3542801/fr/blincyto-blinatumomab-leucemie-aigue-lymphoblastique
2025
false
false
false
France
blinatumomab
antineoplastic agents
adult
treatment outcome
insurance, health, reimbursement
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Measurable Residual Disease Negativity
consolidation chemotherapy
evaluation of the transparency committee
precursor cell lymphoblastic Leukemia-Lymphoma
blinatumomab

---
https://ansm.sante.fr/tableau-acces-derogatoire/balversa-erdafitinib
2025
false
false
false
France
French
drug information
erdafitinib
administration, oral
erdafitinib

---
https://ansm.sante.fr/tableau-acces-derogatoire/rybrevant
2025
false
false
false
France
French
summary of product characteristics
amivantamab
Antineoplastic Agents, Immunological
amivantamab
advanced non-small cell lung cancer with activating epidermal growth factor receptor exon 20 insertion mutations
carcinoma, non-small-cell lung
guidelines for drug use
package leaflet
EGFR Exon 19 Deletion Mutation
EGFR NP_005219.2:p.L858R
EGFR Exon 20 Insertion Mutation

---
https://ansm.sante.fr/tableau-marr/lisocabtagene-maraleucel
2025
false
false
false
France
French
guidelines for drug use
risk management
Lisocabtagene Maraleucel
Lisocabtagene Maraleucel
Product containing only lisocabtagene maraleucel in parenteral dose form (medicinal product form)
Cytokine Release Syndrome
continuity of patient care
gene therapy
immunotherapy, adoptive
signs and symptoms
nervous system diseases
patients guideline
lisocabtagene maraleucel

---
https://ansm.sante.fr/tableau-acces-derogatoire/jakavi-5-mg-comprime
2025
false
false
false
France
French
insurance, health, reimbursement
ruxolitinib phosphate
ruxolitinib
administration, oral
graft vs host disease
Steroid Refractory Graft Versus Host Disease
acute disease
chronic disease
pharmaceutical solutions
child
guidelines for drug use
summary of product characteristics
package leaflet
tablets

---
https://ansm.sante.fr/tableau-marr/fentanyl-8
2025
false
false
false
France
French
fentanyl
patients guideline
guidelines for drug use
risk management
video recording
guideline
fentanyl

---
https://ansm.sante.fr/tableau-acces-derogatoire/enfortumab-vedotin-padcev
2025
false
false
false
France
French
drug information
insurance, health, reimbursement
enfortumab vedotin
enfortumab vedotin
Locally Advanced Urothelial Carcinoma
carcinoma, transitional cell
urologic neoplasms
Metastatic Urothelial Carcinoma
neoplasm metastasis
Refractory Urothelial Carcinoma
infusions, intravenous
antineoplastic agents
antineoplastic combined chemotherapy protocols
pembrolizumab
Enfortumab Vedotin/Pembrolizumab Regimen
Unresectable Urothelial Carcinoma

---
https://ansm.sante.fr/tableau-acces-derogatoire/ivosidenib
2025
false
false
false
France
French
administration, oral
summary of product characteristics
cholangiocarcinoma
guidelines for drug use
leukemia, myeloid, acute
glioma
myelodysplastic syndromes
antineoplastic agents
ivosidenib
ivosidenib
neoplasm metastasis
package leaflet
antineoplastic combined chemotherapy protocols

---
https://ansm.sante.fr/tableau-acces-derogatoire/tedopi
2025
false
false
false
France
French
drug information
insurance, health, reimbursement
injections, subcutaneous
cancer vaccines
Multi-neo-epitope Vaccine OSE 2101

---
https://ansm.sante.fr/tableau-marr/idecabtagene-vicleucel
2025
false
false
false
France
French
guidelines for drug use
popular works
risk management
idecabtagene vicleucel
idecabtagene vicleucel
Drug-Related side effects and adverse reactions
Drug-Related side effects and adverse reactions
Cytokine Release Syndrome
drug compounding
idecabtagene vicleucel
gene therapy
immunotherapy, adoptive
idecabtagene vicleucel
continuity of patient care
nervous system diseases
infusions, intravenous
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
multiple myeloma
Cytokine Release Syndrome
Cytokine Release Syndrome
signs and symptoms
defrosting

---
https://ansm.sante.fr/tableau-acces-derogatoire/teclistamab
2025
false
false
false
France
French
drug information
Teclistamab
adult
multiple myeloma
Recurrent Multiple Myeloma
Refractory Multiple Myeloma
summary of product characteristics
package leaflet
antibodies, monoclonal
Antineoplastic Agents, Immunological
teclistamab

---
https://ansm.sante.fr/tableau-acces-derogatoire/enhertu-100-mg-poudre-pour-solution-a-diluer-pour-perfusion
2025
false
false
false
France
French
summary of product characteristics
package leaflet
guidelines for drug use
Metastatic Gastric Adenocarcinoma
stomach neoplasms
adenocarcinoma
neoplasm metastasis
Locally Advanced Gastric Adenocarcinoma
Metastatic Gastroesophageal Junction Adenocarcinoma
Locally Advanced Gastroesophageal Junction Adenocarcinoma
HER2/Neu Positive
trastuzumab deruxtecan
infusions, intravenous
trastuzumab deruxtecan
Antineoplastic Agents, Immunological
breast neoplasms
Metastatic HER2-Positive Breast Carcinoma
Unresectable HER2-Positive Breast Carcinoma
Refractory HER2-Positive Breast Carcinoma
HER2-Low Breast Carcinoma
Metastatic HER2-Low Breast Carcinoma
neoplasm recurrence, local

---
https://ansm.sante.fr/tableau-acces-derogatoire/imfinzi-50-mg-ml-solution-a-diluer-pour-perfusion
2025
false
false
false
France
French
summary of product characteristics
package leaflet
durvalumab
guidelines for drug use
Unresectable Biliary Tract Carcinoma
antineoplastic combined chemotherapy protocols
Metastatic Biliary Tract Carcinoma
durvalumab
adult
Cisplatin/Durvalumab/Gemcitabine Regimen
infusions, intravenous
cisplatin
carcinoma, hepatocellular
carcinoma, non-small-cell lung
small cell lung carcinoma
bronchial neoplasms

---
https://www.ema.europa.eu/en/medicines/human/EPAR/rybrevant
2025
false
false
false
Netherlands
French
English
amivantamab
amivantamab
amivantamab
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
rybrevant
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
adult
aged
carcinoma, non-small-cell lung
bronchial neoplasms
Activating EGFR Exon 20 Mutation
carcinoma, non-small-cell lung
bronchial neoplasms
Gain of Function Mutation
genes, erbb-1
Refractory Lung Non-Small Cell Carcinoma
infusions, intravenous
product surveillance, postmarketing
pregnancy
breast feeding
drug interactions
drug evaluation, preclinical
Non-small cell lung cancer with mutation in epidermal growth factor receptor (disorder)
advanced non-small cell lung cancer with activating epidermal growth factor receptor exon 20 insertion mutations
EGFR Exon 19 Deletion Mutation
EGFR NP_005219.2:p.L858R

---
https://ansm.sante.fr/tableau-acces-derogatoire/velcade-1-mg-poudre-pour-solution-injectable
2025
false
false
false
France
French
drug information
Bortezomib
injections, intravenous
Immunoglobulin Light-chain Amyloidosis
Non-amyloid monoclonal immunoglobulin deposition disease

---
https://ansm.sante.fr/tableau-acces-derogatoire/xalkori
2025
false
false
false
France
French
drug information
administration, oral
Crizotinib
antineoplastic agents
protein kinase inhibitors
capsules
pharmaceutical solutions
child
infant
lymphoma, large-cell, anaplastic
Childhood Anaplastic Large Cell Lymphoma, ALK-Positive
crizotinib
MET Exon 14 Mutation
Locally Advanced Lung Non-Small Cell Carcinoma
adult
Metastatic Lung Non-Small Cell Carcinoma
carcinoma, non-small-cell lung
continuity of patient care

---
https://ansm.sante.fr/tableau-acces-derogatoire/lutathera
2025
false
false
false
France
French
infusions, intravenous
drug information
lutetium (177Lu) oxodotreotide
lutetium Lu 177 dotatate
radiopharmaceuticals
guidelines for drug use
Pheochromocytoma-paraganglioma
pheochromocytoma
Metastatic Lung Neuroendocrine Tumor
bronchial neoplasms
neoplasm metastasis
Thymic neuroendocrine tumor
neuroendocrine tumors
thymus neoplasms
Metastatic Thymus Neuroendocrine Neoplasm
meningioma
Somatostatin Receptor Positive
Somatostatin Receptor 2 Positive
technical report

---
https://ansm.sante.fr/tableau-acces-derogatoire/thalidomide-bms-50-mg-gelule
2025
false
false
false
France
French
guidelines for drug use
continuity of patient care
thalidomide
administration, oral
Jessner lymphocytic infiltration of the skin
lupus erythematosus, cutaneous
stomatitis, aphthous
Immune complex reaction co-occurrent and due to multibacillary leprosy (disorder)
crohn disease
erythema multiforme
Erythema multiforme major
technical report

---
https://ansm.sante.fr/tableau-acces-derogatoire/opdivo-nivolumab-solution-a-diluer-pour-perfusion-yervoy-ipilimumab-solution-a-diluer-pour-perfusion
2025
false
false
false
France
French
guidelines for drug use
Nivolumab
Ipilimumab/Nivolumab Regimen
Ipilimumab
Antineoplastic Agents, Immunological
Malignant Pleural Mesothelioma
disease progression
Progressive Neoplastic Disease
infusions, intravenous
continuity of patient care
drug monitoring
carcinoma, non-small-cell lung
melanoma
Stage IIB Cutaneous Melanoma AJCC v6 and v7
Stage IIIB Cutaneous Melanoma AJCC v7
technical report

---
https://ansm.sante.fr/tableau-atu-rtu/abecma-260-500-x-106-cellules-dispersion-pour-perfusion
2025
false
false
false
France
French
guidelines for drug use
Idecabtagene Vicleucel
Idecabtagene Vicleucel
gene therapy
immunotherapy, adoptive
adult
multiple myeloma
recurrence
Refractory Multiple Myeloma
idecabtagene vicleucel
idecabtagene vicleucel
Recurrent Multiple Myeloma
genetic therapy

---
https://ansm.sante.fr/tableau-marr/fentanyl-4
2025
false
false
false
France
French
fentanyl
risk management
narcotics
analgesics, opioid
guidelines for drug use
patients guideline
administration, buccal
Orally Disintegrating Film Dosage Form
fentanyl

---
https://ansm.sante.fr/tableau-marr/fentanyl-5
2025
false
false
false
France
French
administration, sublingual
fentanyl
analgesics, opioid
risk management
narcotics
guidelines for drug use
patients guideline
fentanyl
Sublingual Tablet Dosage Form

---
https://ansm.sante.fr/tableau-marr/alpelisib
2025
false
false
false
France
French
guidelines for drug use
administration, oral
Drug-Related side effects and adverse reactions
alpelisib
Alpelisib
Alpelisib
continuity of patient care
Hyperglycaemic hyperosmolar nonketotic syndrome
hyperglycemia
ketosis
thiazoles
thiazoles

---
https://ansm.sante.fr/tableau-acces-derogatoire/selpercatinib-20-40-et-80mg-gelule
2025
false
false
false
France
French
selpercatinib
administration, oral
carcinoma, non-small-cell lung
advanced RET fusion-positive non-small cell lung cancer
Product containing only selpercatinib in oral dose form (medicinal product form)
thyroid cancer, medullary
drug information
selpercatinib
pyrazoles
pyridines

---
https://ansm.sante.fr/tableau-acces-derogatoire/venclyxto-10-mg-50mg-100-mg-comprimes-pellicules?#
2025
false
false
false
France
French
venetoclax
venetoclax
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia
leukemia, myeloid, acute
precursor cell lymphoblastic Leukemia-Lymphoma
Refractory Acute Lymphoblastic Leukemia
Recurrent Acute Lymphoblastic Leukemia
leukemia, lymphocytic, chronic, B-Cell
drug information
Product containing only venetoclax in oral dose form (medicinal product form)
guidelines for drug use
sulfonamides
Bridged Bicyclo Compounds, Heterocyclic
sulfonamides
Bridged Bicyclo Compounds, Heterocyclic

---
https://ansm.sante.fr/tableau-marr/lutecium-177lu-oxodotreotide
2025
false
false
false
France
French
lutetium Lu 177 dotatate
risk management
patients guideline
lutetium Lu 177 dotatate
infusions, intravenous
radiotherapy
radiopharmaceuticals
radiopharmaceuticals
neuroendocrine tumors
lutetium (177Lu) oxodotreotide
drug information
organometallic compounds
octreotide
octreotide
organometallic compounds
octreotide

---
https://ansm.sante.fr/tableau-marr/pomalidomide
2025
false
false
false
France
French
risk management
pregnancy
contraception
teratogens
abnormalities, drug-induced
multiple myeloma
pomalidomide
continuity of patient care
Drug-Related side effects and adverse reactions
risk factors
guidelines for drug use
thrombocytopenia
neutropenia
blood cell count
thromboembolism
Infections
patient education handout
pregnancy tests
forms
thalidomide
thalidomide

---
https://www.has-sante.fr/jcms/p_3633266/fr/ayvakyt-avapritinib-tumeurs-stromales-gastro-intestinales-gist
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
avapritinib
adult
PDGFRA NP_006197.1:p.D842V
gastrointestinal stromal tumors
PDGFRA Gene Mutation
evaluation of the transparency committee
gastrointestinal stromal tumors
avapritinib

---
https://www.has-sante.fr/jcms/p_3633406/fr/welireg-belzutifan-maladie-de-von-hippel-lindau
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
belzutifan
adult
guidelines for drug use
administration, oral
antineoplastic agents
evaluation of the transparency committee
von Hippel-Lindau disease
belzutifan

---
https://www.has-sante.fr/jcms/p_3633368/fr/blincyto-blinatumomab-leucemie-aigue-lymphoblastique-lal-chez-l-adulte-de-18-a-30-ans
2025
France
evaluation of the transparency committee
blinatumomab
precursor cell lymphoblastic Leukemia-Lymphoma
Blincyto
leukaemia
adult
due to
blinatumomab
lymphoblast
adulthood
leukemia

---
https://www.has-sante.fr/jcms/p_3633450/fr/onivyde-pegylated-liposomal-irinotecan-liposomal-pegyle-cancer-du-pancreas-metastatique
2025
France
evaluation of the transparency committee
neoplasm, malignant
pancreatic neoplasms
etirinotecan pegol
Irinotecan
cancer of pancreas
malignant neoplasm pancreas
irinotecan

---
https://www.has-sante.fr/jcms/p_3633391/fr/jakavi-ruxolitinib-gvhd-maladie-du-greffon-contre-l-hote-chez-le-nourrisson
2025
France
evaluation of the transparency committee
graft versus host disease, nos
infant
ruxolitinib
graft vs host disease
ruxolitinib

---
https://www.has-sante.fr/jcms/p_3633454/fr/retsevmo-selpercatinib-cancer-de-la-thyroide-et-cancer-bronchique-non-a-petites-cellules
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, oral
tablets
antineoplastic agents
RET Inhibitor
advanced RET fusion-positive non-small cell lung cancer
adult
thyroid cancer, medullary
adolescent
RET Fusion Positive
RET Gene Mutation
evaluation of the transparency committee
carcinoma, non-small-cell lung
selpercatinib
thyroid neoplasms

---
https://www.has-sante.fr/jcms/p_3589932/fr/padcev-enfortumab-vedotin-carcinome-urothelial
2025
France
evaluation of the transparency committee
enfortumab vedotin
enfortumab vedotin
carcinoma

---
https://www.has-sante.fr/jcms/p_3634549/fr/gardasil-9-vaccin-papillomavirus-humain-9-valent-recombinant-adsorbe-vaccin-hpv
2025
France
evaluation of the transparency committee
Gardasil 9
human papillomavirus vaccines
vaccination
papillomaviridae
preventive immunization/medication
viral disease other/nos
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
vaccine, nos
human papillomavirus, nos

---
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015786.pub2/full/fr
2025
United Kingdom
review of literature
french abstract
endometrial neoplasms
sentinel lymph node biopsy
endometrium
cancer
patient care management
neoplasm, malignant
Endomet
biopsy, nos

---
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014818.pub2/full/fr
2025
United Kingdom
review of literature
french abstract
analgesia
breast cancer
general surgery
operative procedure, nos
pain, nos
Cancer Pain
neoplasm, malignant
analgesia
pain, postoperative
reticulum
breast neoplasms

---
https://conseil-scientifique.public.lu/fr/publications/oncologie/referentiel-national-pour-le-depistage-du-cancer-du-sein-en-fonction-du-risque-2025.html
2025
Luxembourg
guideline
screening for cancer
early detection of cancer
breast neoplasms
risk
breast cancer
risk assessment
cancer screening
breast function, nos

---
https://www.has-sante.fr/jcms/p_3590639/fr/imfinzi-lynparza-durvalumab/olaparib-cancer-de-l-endometre
2025
false
false
false
France
antineoplastic combined chemotherapy protocols
insurance, health, reimbursement
treatment outcome
Antineoplastic Agents, Immunological
Advanced Endometrial Carcinoma
Recurrent Endometrial Carcinoma
Mismatch Repair Proficient
Mismatch Repair Deficiency
durvalumab
durvalumab
olaparib
olaparib
evaluation of the transparency committee
endometrial neoplasms

---
https://ansm.sante.fr/disponibilites-des-produits-de-sante/medicaments/elvorine-25-mg-2-5-ml-50-mg-5-ml-100-mg-10-ml-et-175-mg-17-5-ml-solution-injectable-levofolinate-de-calcium
2025
false
false
false
France
French
drug information
leucovorin, calcium (1:1) salt, (S)-Isomer
levoleucovorin

---
https://ansm.sante.fr/tableau-marr/tremelimumab
2025
false
false
false
France
French
tremelimumab
tremelimumab
risk management
drug information
patient education handout
Immune-Mediated Adverse Reaction
Drug-Related side effects and adverse reactions
signs and symptoms
Drug-Related side effects and adverse reactions

---
https://www.cancer.fr/presse/renforcer-la-securisation-medicamenteuse-des-patients-sous-anticancereux-injectables
2025
France
guideline
antineoplastic agents
injections
patients
hospitalization
drug therapy
hospital, nos
day care center
has patient
hospitals
administration of therapeutic substance, nos

---
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/les-therapies-bispecifiques-et-therapies-par-lymphocytes-t-infiltrant-la-tumeur-considerations-pour-un-deploiement-au-quebec.html
2025
Canada
health technology assessment
quebec
neoplasms
therapy, nos
lymphocytes, tumor-infiltrating
t lymphocyte
T-Lymphocytes
infiltration, nos

---
https://www.calameo.com/onco-occitanie/read/00717809219018063b661
2025
France
scientific and technical information
aged
diet
food
Oncologists
eating, nos
malnutrition

---
https://www.calameo.com/onco-occitanie/read/00717809236de148a34fb
2025
France
scientific and technical information
drug therapy
neoplasms
drug, nos
cancer
home care services, hospital-based
neoplasm, malignant

---
https://www.calameo.com/onco-occitanie/read/0071780926cd369cb630b
2025
France
scientific and technical information
Oncologists
public assistance
aged
socialism
domicile
home health aides

---
https://www.calameo.com/onco-occitanie/read/007178092e2a930832229
2025
France
scientific and technical information
mobility, nos
Oncologists
aged

---
https://www.has-sante.fr/jcms/p_3592985/fr/elahere-mirvetuximab-soravtansine-cancer-de-l-ovaire
2025
false
false
false
France
insurance, health, reimbursement
mirvetuximab soravtansine
infusions, intravenous
adult
fallopian tube neoplasms
peritoneal neoplasms
Folate Receptor Alpha Positive
evaluation of the transparency committee
ovarian neoplasms
mirvetuximab soravtansine

---
https://publications.msss.gouv.qc.ca/msss/document-003869/
2025
Canada
handbooks
antineoplastic agents
route of administration, nos
administration
injections, intramuscular
nursing care
nursing care, nos
nurse administrators
subcutaneous tissue, nos
protestantism
antineoplastic agent, nos

---
https://ansm.sante.fr/tableau-acces-derogatoire/elahere
2025
false
false
false
France
French
insurance, health, reimbursement
mirvetuximab soravtansine
mirvetuximab soravtansine
drug information
immunoconjugates
antibodies, monoclonal, humanized
maytansine
Antineoplastic Agents, Immunological
Folate Receptor Alpha Positive
ovarian neoplasms
peritoneal neoplasms
fallopian tube neoplasms

---
https://www.santepubliquefrance.fr/maladies-et-traumatismes/cancers/cancer-du-colon-rectum/documents/enquetes-etudes/incidence-et-son-evolution-entre-2000-et-2020-des-cancers-chez-les-adolescents-et-jeunes-adultes-15-39-ans-dans-les-departements-francais-couvert
2025
France
technical report
Personal Protective Equipment
neoplasm, malignant
adult children
adolescence
french
young adult
reticulum
incidence
cancer
adolescent
neoplasms
general practitioners
adulthood
registers
france

---
https://www.has-sante.fr/jcms/p_3594390/fr/vitrakvi-larotrectinib-sarcome-des-tissus-mous-cancer-des-glandes-salivaires-cancer-de-la-thyroide-non-medullaire
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
Tyrosine Kinase Inhibitors
larotrectinib
TRK Inhibitor
nonmedullary thyroid carcinoma
adult
NTRK Fusion Gene Positive
Solid neoplasm with neurotrophic receptor tyrosine kinase gene fusion (disorder)
evaluation of the transparency committee
salivary gland neoplasms
larotrectinib
sarcoma
thyroid neoplasms

---
https://www.has-sante.fr/jcms/p_3594155/fr/vyloy-zolbetuximab-adenocarcinome-gastrique-et-de-la-jonction-oesogastrique
2025
false
false
false
France
stomach neoplasms
esophageal neoplasms
treatment outcome
insurance, health, reimbursement
zolbetuximab
infusions, intravenous
Antineoplastic Agents, Immunological
antineoplastic combined chemotherapy protocols
adult
Gastroesophageal Junction Adenocarcinoma
Gastric Adenocarcinoma
CLDN18.2 Positive
HER2/Neu Negative
evaluation of the transparency committee
adenocarcinoma
zolbetuximab
esophagogastric junction

---
https://ansm.sante.fr/tableau-marr/isatuximab
2025
false
false
false
France
French
risk management
isatuximab
guideline
patient education handout
blood transfusion
indirect coombs test
Laboratory test interference

---
https://www.cochrane.org/fr/CD015517/CENTRALED_lentrainement-cardiovasculaire-avant-pendant-ou-apres-le-traitement-anticancereux-soulage-t-il-la
2025
United Kingdom
review of literature
french abstract
cancer
antineoplastic agents
neoplasm, malignant
fatigue
fatigue
neoplasms

---
https://www.has-sante.fr/jcms/p_3597238/fr/calquence-acalabrutinib-lymphome-a-cellules-du-manteau-lcm
2025
false
false
false
France
evaluation of the transparency committee
Calquence
"u" lymphocyte
lymphoma, mantle-cell
acalabrutinib
acalabrutinib
malignant lymphoma, nos

---
https://www.canal-u.tv/chaines/ut2j/l-intelligence-methodes-pratiques-outils-et-objets-scientifiques-en-dialogue/l
2025
France
audiovisual aids
diagnosis
no diagnosis
diagnosis, computer-assisted
medical oncology
intelligence, nos
artificial intelligence
pathology
anatomic pathologist

---
https://www.has-sante.fr/jcms/p_3597606/fr/krazati-adagrasib-cancer-bronchique-non-a-petites-cellules-avance-cbnpc
2025
false
false
false
France
bronchial neoplasms
treatment outcome
insurance, health, reimbursement
administration, oral
antineoplastic agents
adagrasib
adult
KRAS G12C Inhibitor
KRAS NP_004976.2:p.G12C
evaluation of the transparency committee
carcinoma, non-small-cell lung
adagrasib

---
https://www.inspq.qc.ca/publications/3627
2025
Canada
technical report
Program
Portrait
portraits as topic
screening for cancer
mammography, nos
breast cancer
cancer screening
early detection of cancer
breast neoplasms
mammography

---
https://www.has-sante.fr/jcms/p_3598458/fr/enhertu-trastuzumab-deruxtecan-cancer-du-sein-her2-faible-ou-ultra-faible
2025
false
false
false
France
evaluation of the transparency committee
breast neoplasms
Trastuzumab
trastuzumab deruxtecan
trastuzumab

---
https://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Oncologie/Biomarqueurs_Cancer_vessie_EC_INESSS.pdf
2025
Canada
review of literature
persons
neoplasm, malignant
urinary bladder cancer
tumor burden
neoplasms
patient care management
malignant neoplasm of bladder
urinary bladder neoplasms
Biomarkers
disease

---
https://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Oncologie/EC_Biomarqueurs_Cancer_col_uterin_INESSS.pdf
2025
Canada
review of literature
tumor burden
persons
uterus, nos
patient care management
uterine cervical neoplasms
Biomarkers
cancer
disease
neoplasms
neoplasm, malignant

---
https://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Oncologie/EC_Cancer_prostate_biomarqueurs_INESSS.pdf
2025
Canada
review of literature
tumor burden
malignant neoplasm prostate
Biomarkers
disease
persons
prostatism, nos
prostate cancer
prostate, nos
neoplasm, malignant
patient care management
prostatic neoplasms

---
https://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Oncologie/INESSS_Biomarqueurs_Cholangiocarcinome_EC_VF.pdf
2025
Canada
review of literature
Biomarkers
tumor burden
patient care management
disease
cholangiocarcinoma
persons
cholangiocarcinoma
neoplasms

---
https://www.ema.europa.eu/en/medicines/human/EPAR/eribulin-baxter
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
eribulin mesylate
eribulin mesylate
drugs, generic

---
https://www.ema.europa.eu/en/medicines/human/EPAR/apexelsin
2025
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
paclitaxel
paclitaxel

---
https://www.ema.europa.eu/en/medicines/human/EPAR/balversa
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
erdafitinib
erdafitinib
erdafitinib
drug approval
europe
Balversa
Metastatic Urothelial Carcinoma
Unresectable Urothelial Carcinoma
urologic neoplasms
adult
urologic neoplasms
FGFR3 Gene Alteration Positive
administration, oral
continuity of patient care
Tyrosine Kinase Inhibitors
Tyrosine Kinase Inhibitors
FGFR Inhibitor
FGFR Inhibitor
risk management
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
Female of Childbearing Potential
antineoplastic agents
antineoplastic agents
drug evaluation, preclinical

---
https://www.ema.europa.eu/en/medicines/human/EPAR/tuznue
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
Trastuzumab
Trastuzumab
biosimilar pharmaceuticals

---
https://www.ema.europa.eu/en/medicines/human/EPAR/vyloy
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
treatment outcome
zolbetuximab
zolbetuximab
orphan drug production
zolbetuximab
drug approval
europe
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
infusions, intravenous
antibodies, monoclonal
antibodies, monoclonal
stomach neoplasms
esophageal neoplasms
adenocarcinoma
antineoplastic combined chemotherapy protocols
Metastatic Gastric Adenocarcinoma
Locally Advanced Unresectable Gastric Adenocarcinoma
Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma
Metastatic Gastroesophageal Junction Adenocarcinoma
CLDN18.2 Positive
HER2/Neu Negative
product surveillance, postmarketing
adult
aged
CLDN18 protein, human
Anti-claudin18.2 Monoclonal Antibody
pregnancy
breast feeding
drug evaluation, preclinical

---
https://www.ema.europa.eu/en/medicines/human/EPAR/elahere
2025
false
false
false
Netherlands
French
English
syndication feed
summary of product characteristics
package leaflet
treatment outcome
mirvetuximab soravtansine
mirvetuximab soravtansine
infusions, intravenous
drug approval
europe
ovarian neoplasms
fallopian tube neoplasms
peritoneal neoplasms
risk management
product surveillance, postmarketing
mirvetuximab soravtansine
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized
Maytansinoid DM4
Mirvetuximab
premedication
pregnancy
breast feeding
tubulin modulators
tubulin modulators
folate receptor 1
Antibody-Drug Conjugates
immunoconjugates
drug evaluation, preclinical
Folate Receptor Alpha Positive

---
https://minerva-ebp.be/FR/Article/2428
2025
Belgium
critical appraisal or critical reading
prostate, nos
magnetic resonance imaging, nos
magnetic resonance imaging
lesion, nos
prostate cancer
wounds and injuries
cancer screening
screening for cancer
prostatic neoplasms
due to
early detection of cancer
malignant neoplasm prostate
prostatism, nos

---
https://minerva-ebp.be/FR/Article/2430
2025
Belgium
critical appraisal or critical reading
screening for cancer
cancer screening
breast cancer
patients
breast neoplasms
early detection of cancer
has patient

---
https://www.has-sante.fr/jcms/p_3601434/fr/verzenios-abemaciclib-cancer-du-sein
2025
false
false
false
France
hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer
menopause
evaluation of the transparency committee
abemaciclib
breast neoplasms
abemaciclib
breast cancer
Verzenio
neoplasm, malignant

---
https://www.has-sante.fr/jcms/p_3601428/fr/kisqali-ribociclib-cancer-du-sein
2025
false
false
false
France
treatment outcome
hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer
evaluation of the transparency committee
neoplasm, malignant
Kisqali
breast cancer
ribociclib
breast neoplasms
ribociclib

---
https://ansm.sante.fr/informations-de-securite/kisqali-ribociclib-changement-des-conditions-de-conservation-et-de-la-duree-de-conservation
2025
false
false
false
France
French
drug information
guideline
drug storage
ribociclib

---
https://www.cochrane.org/fr/CD014872/CENTRALED_le-choix-de-therapies-ciblees-basees-sur-les-tests-genetiques-du-cancer-dune-personne-prolonge-t-il
2025
United Kingdom
review of literature
french abstract
disease
life expectancy
life
choice behavior
genetta, nos
therapy, nos
genetic therapy
cancer
life support care
long
disease progression
disease, nos
neoplasms
gene, nos
persons
neoplasm, malignant

---
https://www.has-sante.fr/jcms/p_3601719/fr/elahere-mirvetuximab-soravtansine-cancer-de-l-ovaire
2025
false
false
false
France
French
treatment outcome
insurance, health, reimbursement
Antineoplastic Agents, Immunological
mirvetuximab soravtansine
mirvetuximab soravtansine
adult
ovarian neoplasms
fallopian tube neoplasms
peritoneal neoplasms
evaluation of the transparency committee
Folate Receptor Alpha Positive

---
https://www.has-sante.fr/jcms/p_3453321/fr/pluvicto-177lu-cancer-de-la-prostate
2025
false
false
false
treatment outcome
insurance, health, reimbursement
antineoplastic combined chemotherapy protocols
metastatic castration resistant prostate cancer
Metastatic Castration-Resistant Prostate Carcinoma
evaluation of the transparency committee
prostatic neoplasms, Castration-Resistant

---
https://www.chu-lyon.fr/cancer-mesotheliome
2025
France
popular works
pleural neoplasms
neoplasm, malignant
cancer
pleura
mesothelioma

---
https://www.cochrane.org/fr/CD015551/CENTRALED_quels-sont-les-benefices-et-risques-des-vaccins-pour-la-prevention-des-maladies-infectieuses-chez
2025
United Kingdom
review of literature
french abstract
vaccinia, nos
infection control
disease
communicable diseases
vaccine, nos
cancer
vaccination, nos
preventive immunization/medication
infectious disease, nos
vaccines
risks and benefits
adult disease, nos
neoplasm, malignant
vaccination
infectious diseases
risk assessment
adult
neoplasms

---
https://www.has-sante.fr/jcms/p_3604202/fr/rybrevant-amivantamab-cancer-bronchique-non-a-petites-cellules-exon-19-exon-21
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
amivantamab
Non-small cell lung cancer with mutation in epidermal growth factor receptor (disorder)
bronchial neoplasms
infusions, intravenous
Antineoplastic Agents, Immunological
antibodies, bispecific
Amivantamab/Carboplatin/Pemetrexed Regimen
antineoplastic combined chemotherapy protocols
carboplatin
Pemetrexed
adult
EGFR NP_005219.2:p.L858R
EGFR Exon 19 Deletion Mutation
evaluation of the transparency committee
amivantamab
bronchial neoplasms

---
https://www.has-sante.fr/jcms/p_3605179/fr/tagrisso-osimertinib-cancer-du-poumon
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, oral
osimertinib
antineoplastic agents
Tyrosine Kinase Inhibitors
adult
EGFR Exon 19 Deletion Mutation
EGFR NP_005219.2:p.L858R
Locally Advanced Unresectable Lung Non-Small Cell Carcinoma
lung neoplasms
Non-small cell lung cancer with mutation in epidermal growth factor receptor (disorder)
evaluation of the transparency committee
lung neoplasms
osimertinib

---
https://www.has-sante.fr/jcms/p_3604199/fr/rybrevant-amivantamab-cancer-bronchique-non-a-petites-cellules-exon-20
2025
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
antibodies, bispecific
amivantamab
amivantamab
infusions, intravenous
Antineoplastic Agents, Immunological
bronchial neoplasms
carcinoma, non-small-cell lung
antineoplastic combined chemotherapy protocols
Amivantamab/Carboplatin/Pemetrexed Regimen
carboplatin
Pemetrexed
adult
Non-small cell lung cancer with mutation in epidermal growth factor receptor (disorder)
advanced non-small cell lung cancer with activating epidermal growth factor receptor exon 20 insertion mutations

---
https://boutique.liguecancer.ch/files/kls/webshop/PDFs/francais/travail-finances-et-decisions-medicales-en-cas-de-cancer-021813012111.pdf
2025
Switzerland
patient education handout
financial support
cancer
snacks
neoplasms
work
neoplasm, malignant
occupation, nos

---
https://minerva-ebp.be/Theme/Analysis/907
2025
Belgium
critical appraisal or critical reading
cancer screening
early detection of cancer
life
screening for cancer

---
https://www.cochrane.org/fr/CD010145/CENTRALED_pour-les-patients-atteints-de-cancer-quels-sont-les-benefices-et-risques-de-la-prise-de-melatonine
2025
United Kingdom
review of literature
french abstract
risk assessment
disease
patients
risk-taking
cancer
melatonin
neoplasms
has patient
melatonin
neoplasm, malignant
risks and benefits

---
https://www.has-sante.fr/jcms/p_3609063/fr/elrexfio-elranatamab-myelome-multiple
2025
false
false
false
France
Elranatamab
elranatamab
relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy
treatment outcome
insurance, health, reimbursement
evaluation of the transparency committee
multiple myeloma

---
https://www.has-sante.fr/jcms/p_3609085/fr/imfinzi-durvalumab-cancer-de-la-vessie
2025
false
false
false
France
evaluation of the transparency committee
durvalumab
malignant neoplasm of bladder
Imfinzi
neoplasm, malignant
urinary bladder cancer
urinary bladder neoplasms
durvalumab

---
https://www.ema.europa.eu/en/medicines/human/EPAR/welireg
2025
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
administration, oral
belzutifan
belzutifan
belzutifan
antineoplastic agents
antineoplastic agents
HIF-2alpha Inhibitor
HIF-2alpha Inhibitor
risk management
product surveillance, postmarketing
clear cell renal cell carcinoma
Advanced Clear Cell Renal Cell Carcinoma
Refractory Clear Cell Renal Cell Carcinoma
adult
von Hippel-Lindau disease
Central Nervous System Hemangioblastoma
carcinoma, renal cell
Pancreatic Neuroendocrine Tumor
Unresectable Pancreatic Neuroendocrine Tumor
EPAS1 protein, human
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical

---
https://minerva-ebp.be/FR/Article/2441
2025
Belgium
critical appraisal or critical reading
cancer
disease
efficiency
patients
neoplasm, malignant
psychology, comparative
neoplasms
has patient
Psychosocial Intervention

---
https://www.has-sante.fr/jcms/p_3609960/fr/protocole-d-evaluation-de-l-acte-de-radiotherapie-peroperatoire-rtpo-adjuvante-a-la-tumorectomie-dans-le-traitement-du-cancer-du-sein-precoce-a-faible-risque-de-recidive
2025
France
health technology assessment
asthenia
early therapy
secondary prevention
radiotherapy
risk
due to
breast neoplasms
neoplasm, malignant
mastectomy, segmental
adjuvant, nos
tylectomy, nos
radiation therapy, nos
recurrence
evaluation studies as topic
breast cancer

---
https://www.cancer.fr/catalogue-des-publications/agir-pour-sa-sante-contre-les-risques-de-cancer2
2024
false
false
false
France
Healthy Lifestyle
neoplasms
patient education handout
risk
health
Cancer
neoplasms
risk
cancer
hazardous substances
health
neoplasm, malignant

---
2024
false
false
false
France
French
osimertinib
summary of product characteristics
package leaflet
guidelines for drug use
administration, oral
carcinoma, non-small-cell lung
carcinoma, non-small-cell lung
mutation
bronchial neoplasms
bronchial neoplasms
EGF Receptors
antineoplastic agents
antineoplastic agents
protein kinase inhibitors
protein kinase inhibitors
osimertinib
EGFR NP_005219.2:p.L858R
EGFR Exon 19 Deletion Mutation
ErbB Receptors
acrylamides
aniline compounds

---
https://cancer.be/cancer/le-cancer/
2024
false
false
false
Belgium
neoplasms
neoplasms
neoplasms
neoplasms
popular works

---
https://ansm.sante.fr/tableau-atu-rtu/kymriah-1-2-x-106-6-x-108-cellules-dispersion-pour-perfusion
2024
false
false
false
France
French
guidelines for drug use
summary of product characteristics
package leaflet
tisagenlecleucel
tisagenlecleucel
lymphoma, follicular
adult
Refractory Follicular Lymphoma
Recurrent Follicular Lymphoma
tisagenlecleucel
risk management
infusions, intravenous
antineoplastic agents
antineoplastic agents
patients guideline

---
https://ansm.sante.fr/tableau-acces-derogatoire/yescarta-0-4-2-x-108-cellules-dispersion-pour-perfusion#
2024
false
false
false
France
French
axicabtagene ciloleucel
axicabtagene ciloleucel
biological products
Antineoplastic Agents, Immunological
Recurrent High Grade B-Cell Lymphoma
lymphoma, large B-Cell, diffuse
adult
Refractory High Grade B-Cell Lymphoma
drug information
immunotherapy, adoptive
antigens, CD19

---
https://ansm.sante.fr/tableau-marr/atezolizumab
2024
false
false
false
France
French
atezolizumab
atezolizumab
atezolizumab
Drug-Related side effects and adverse reactions
risk management
drug information
patient education handout
Drug-Related side effects and adverse reactions
signs and symptoms
antineoplastic agents
antineoplastic agents
immune system diseases
immune system diseases
antibodies, monoclonal
antibodies, monoclonal

---
https://ansm.sante.fr/tableau-marr/lenalidomide
2024
false
false
false
France
French
risk management
pregnancy
contraception
lenalidomide
multiple myeloma
lymphoma, mantle-cell
teratogens
continuity of patient care
drug monitoring
clinical chemistry tests
myelodysplastic syndromes
guidelines for drug use
popular works
venous thromboembolism
Tumor Flare Reaction
neoplasms
Chemical and Drug Induced Liver Injury
angiogenesis inhibitors
angiogenesis inhibitors
thalidomide
thalidomide
thalidomide
Lenalidomide
Lenalidomide

---
https://ansm.sante.fr/tableau-marr/pembrolizumab
2024
false
false
false
France
French
risk management
pembrolizumab
Infusion related reaction
immune system diseases
Drug-Related side effects and adverse reactions
patient education handout
pregnancy
continuity of patient care
drug monitoring
Antineoplastic Agents, Immunological
pembrolizumab
antibodies, monoclonal
antibodies, monoclonal, humanized

---
https://ansm.sante.fr/tableau-marr/rituximab
2024
false
false
false
France
French
risk management
Rituximab
Rituximab
infusions, intravenous
injections, subcutaneous
rituximab
risk
leukoencephalopathy, progressive multifocal
Infections
Drug-Related side effects and adverse reactions
continuity of patient care
drug monitoring
patient education handout
drug compounding

---
https://ansm.sante.fr/tableau-marr/sonidegib
2024
false
false
false
France
French
risk management
sonidegib
teratogens
pregnancy
abnormalities, drug-induced
contraception
pregnancy tests
antineoplastic agents
fetal death
patient education handout
guidelines for drug use
guideline
sonidegib
biphenyl compounds
pyridines

---
https://ansm.sante.fr/tableau-marr/thalidomide
2024
false
false
false
France
French
risk management
thalidomide
teratogens
abnormalities, drug-induced
pregnancy
thalidomide
guideline
forms
patient education handout
continuity of patient care
Neuropathy peripheral
thromboembolism
Drug-Related side effects and adverse reactions
pregnancy tests
contraception
package leaflet

---
https://ansm.sante.fr/tableau-marr/vandetanib
2024
false
false
false
France
French
risk management
vandetanib
vandetanib
Cardiotoxicity
adult
child
posterior leukoencephalopathy syndrome
death, sudden
long qt syndrome
torsades de pointes
continuity of patient care
drug monitoring
drug interactions
medication errors
vandetanib
handbooks
popular works
RET Gene Mutation
guidelines for drug use
piperidines
quinazolines
piperidines
quinazolines

---
http://publications.msss.gouv.qc.ca/msss/document-000288/
2024
false
false
false
Canada
patient education handout
screening for cancer
Program
breast neoplasms
Breast cancer
breast cancer
cancer screening
early detection of cancer

---
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/depistage-cancer-uterus-recommandations.html
2024
Canada
public health guidelines
early detection of cancer
Cervical Carcinoma
implantation in uterus, nos
Implantation Method of Administration
Detection
Test Dosing Unit
papillomaviridae
Human Papillomavirus Viruses
Cervical Cancer pT1a1 TNM Finding v8
Primary
cancer screening
uterine cervical neoplasms
prostheses and implants
Blood Products Laboratory Testing
Prior Primary
Test Name
dermatomyositis
malignant neoplasm cervix
screening for cancer
Administration via Implantation
Human Papillomavirus
Cervical Cancer Screening
Biological Detection Test
quebec
Altretamine/Etoposide/Procarbazine
human papillomavirus, nos
cancer of the uterine cervix
principal
Primary Cause of Death
detective
health planning guidelines
Implantation

---
https://www.has-sante.fr/jcms/p_3506762/fr/balversa-erdafitinib-carcinome-urothelial
2024
false
false
false
France
erdafitinib
administration, oral
Product containing only erdafitinib in oral dose form (medicinal product form)
evaluation of the transparency committee
erdafitinib
erdafitinib
Erdafitinib

---
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/equivalence-du-seuil-de-positivite-des-tests-immunochimiques-de-recherche-de-sang-occulte-dans-les-selles-pour-le-depistage-du-cancer-colorectal.html
2024
Canada
review of literature
feces
early detection of cancer
Equivalent
screening for occult blood in feces
cancer screening
screening for cancer
Research
Search
research
immunochemistry
Blood in Stool
colorectal neoplasms
Occult Blood Measurement
Colorectal Cancer
Screening for Colorectal Cancer
occult blood
Liquid Tumor
malignant neoplasm colon/rectum

---
https://ansm.sante.fr/tableau-marr/crizotinib
2024
false
false
false
France
French
patients guideline
patient education handout
drug information
risk management
Crizotinib
Crizotinib
continuity of patient care
crizotinib
vision disorders
adult
child

---
https://kce.fgov.be/fr/publications/tous-les-rapports/depistage-du-cancer-du-poumon-chez-les-personnes-a-haut-risque
2024
Belgium
technical report
risk assessment
persons
cancer screening
lung cancer
risk
Screening for Lung Cancer
People
High-Risk Cancer
screening for cancer
early detection of cancer
lung neoplasms

---
https://www.has-sante.fr/jcms/p_3506437/fr/rubraca-rucaparib-cancer-de-l-ovaire
2024
false
false
false
France
fallopian tube neoplasms
peritoneal neoplasms
treatment outcome
insurance, health, reimbursement
administration, oral
rucaparib
evaluation of the transparency committee
rucaparib
ovarian neoplasms
Rucaparib Camsylate

---
https://ansm.sante.fr/disponibilites-des-produits-de-sante/medicaments/novantrone-10-mg-5-ml-solution-a-diluer-pour-perfusion-mitoxantrone-chlorhydrate-de
2024
false
false
false
France
French
drug information
mitoxantrone hydrochloride
mitoxantrone

---
https://ansm.sante.fr/actualites/campagne-vaccinale-contre-les-infections-a-papillomavirus-humains-hpv-les-donnees-recueillies-apres-la-premiere-dose-confirment-le-profil-de-securite-du-vaccin-gardasil-9
2024
false
false
false
France
French
papillomavirus vaccines
papillomavirus infections
vaccine safety
Human Papillomavirus Recombinant Vaccine nonavalent
mass vaccination
Vaccination Campaign
technical report
adolescent
vaccination

---
https://ansm.sante.fr/actualites/decision-du-06-05-2024-renouvellement-du-cpc-du-medicament-imfinzi-durvalumab-50-mg-ml-solution-a-diluer-pour-perfusion
2024
false
false
false
France
French
drug information
durvalumab

---
https://www.has-sante.fr/jcms/p_3512093/fr/talzenna-talazoparib-cancer-de-la-prostate
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
antineoplastic combined chemotherapy protocols
Enzalutamide/Talazoparib Regimen
enzalutamide
metastatic castration resistant prostate cancer
adult
neoplasm metastasis
administration, oral
talazoparib
Poly(ADP-ribose) Polymerase Inhibitors
Product containing only talazoparib in oral dose form (medicinal product form)
evaluation of the transparency committee
talazoparib
prostatic neoplasms, Castration-Resistant

---
https://www.has-sante.fr/jcms/p_3513274/fr/sunitinib-zentiva-sunitinib-oncologie
2024
false
false
false
France
evaluation of the transparency committee
Sunitinib Malate
Oncologist
Sunitinib
Oncology
Sunitinib
Oncologists

---
https://www.has-sante.fr/jcms/p_3516751/fr/akeega-niraparib/acetate-d-abiraterone-cancer-de-la-prostate
2024
false
false
false
France
evaluation of the transparency committee
abiraterone
prostatism, nos
Prostate Carcinoma
prostatic neoplasms
Prostate Cancer pT2c TNM Finding v6 and v7
NCI CTEP SDC Prostate Cancer Sub-Category Terminology
Prostate Cancer Pathway
prostate cancer
neoplasm, malignant
prostate, nos
Abiraterone
abiraterone
malignant neoplasm prostate

---
https://www.has-sante.fr/jcms/p_3515581/fr/finlee-spexotras-dabrafenib-trametinib-gliome-pediatrie
2024
false
false
false
France
insurance, health, reimbursement
treatment outcome
antineoplastic combined chemotherapy protocols
dabrafenib
protein kinase inhibitors
antineoplastic agents
child
infant
Childhood Low Grade Glioma
malignant glioma
Childhood Malignant Glioma
BRAF V600E Mutation Present
guidelines for drug use
package leaflet
summary of product characteristics
Trametinib Dimethyl Sulfoxide
administration, oral
trametinib
evaluation of the transparency committee
dabrafenib
Dabrafenib/Trametinib Regimen
glioma
trametinib

---
https://www.has-sante.fr/jcms/p_3506840/fr/imfinzi-durvalumab-cancer-bronchique-non-a-petites-cellules
2024
false
false
false
France
evaluation of the transparency committee
Imfinzi
Durvalumab
durvalumab
durvalumab

---
https://www.ema.europa.eu/en/medicines/human/EPAR/spexotras
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
trametinib
trametinib
antineoplastic agents
protein kinase inhibitors
administration, oral
drug approval
Trametinib Dimethyl Sulfoxide
orphan drug production
infant
child
europe
trametinib
antineoplastic combined chemotherapy protocols
glioma
Dabrafenib/Trametinib Regimen
Childhood Malignant Glioma
Childhood Low Grade Glioma
malignant glioma
glioma
BRAF V600E Mutation Present
Mitogen-Activated Protein Kinase Kinase Inhibitor
drug evaluation, preclinical

---
https://www.has-sante.fr/jcms/p_3517160/fr/tecentriq-atezolizumab-oncologie
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
Product containing only atezolizumab in parenteral dose form (medicinal product form)
atezolizumab
antineoplastic combined chemotherapy protocols
Atezolizumab/Bevacizumab/Carboplatin/Paclitaxel Regimen
neoplasm metastasis
carcinoma, non-small-cell lung
small cell lung carcinoma
Extensive Stage Lung Small Cell Carcinoma
antineoplastic agents
Unresectable Hepatocellular Carcinoma
Advanced Hepatocellular Carcinoma
carcinoma, hepatocellular
evaluation of the transparency committee
atezolizumab

---
https://www.has-sante.fr/jcms/p_3518105/fr/blincyto-blinatumomab-leucemie-aigue-lymphoblastique-lal-chez-l-adulte
2024
false
false
false
France
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
insurance, health, reimbursement
treatment outcome
antineoplastic agents
blinatumomab
infusions, intravenous
Precursor B-cell acute lymphoblastic leukemia
evaluation of the transparency committee
adult
blinatumomab

---
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/depistage-du-cancer-du-sein-par-tomosynthese-mammaire.html
2024
Canada
public health guidelines
Mammary
breast cancer
Breast Cancer Screening
screening for cancer
Murine Mammary Gland
cancer screening
early detection of cancer
breast, nos
breast neoplasms

---
https://www.assurance-maladie.ameli.fr/etudes-et-donnees/2024-risque-cancer-enfants-procreation-medicalement-assistee
2024
France
scientific and technical information
Childhood Malignant Neoplasm
cancer
Assisted Reproductive Technology
child
neoplasms
Cancer Risk
medical assistant
child, nos
risk
neoplasm, malignant
reproductive techniques, assisted

---
https://www.has-sante.fr/jcms/p_3517411/fr/elrexfio-elranatamab-myelome-multiple
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy
Recurrent Multiple Myeloma
antibodies, monoclonal
Triple-Class Refractory Multiple Myeloma
adult
injections, subcutaneous
Progressive Neoplastic Disease
recurrence
elranatamab
evaluation of the transparency committee
multiple myeloma
Elranatamab

---
https://www.has-sante.fr/jcms/p_3518652/fr/xgeva-denosumab-oncologie
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
injections, subcutaneous
Pre-filled Syringe
bone neoplasms
giant cell tumor of bone
adult
adolescent
fractures, spontaneous
spinal cord compression
evaluation of the transparency committee
Denosumab

---
https://www.rheuma-net.ch/fr/doc/cyclophosphamid-1/viewdocument/348
2024
Switzerland
guideline
cyclophosphamide
cyclophosphamide
Background Treatment
Cyclophosphamide

---
https://www.youtube.com/playlist?list=PLtIOHxI9gZvnBkvv7A1JTvZcn8iZUAdl7
2024
France
popular works
video recording
nicotiana tabacum
Nicotiana
neoplasm, malignant
hypersensitivity
Tobacco Smoking
Sensitization
cancer
neoplasms
Malignant Neoplasm
Smoking Tobacco

---
https://www.has-sante.fr/jcms/p_3519904/fr/imfinzi-durvalumab-et-lynparza-olaparib-en-association-cancer-de-l-endometre
2024
false
false
false
France
antineoplastic combined chemotherapy protocols
endometrial neoplasms
evaluation of the transparency committee
durvalumab
olaparib

---
https://journals.openedition.org/anthropologiesante/13215
2024
France
journal article
New Lesion Identification
Artificial Intelligence
Conception Age
convergence, ocular
Oncologists
artificial intelligence
Breast Cancer Anti-Estrogen Resistance Protein 1
Conception
intelligence, nos
Coronavirus Anxiety Scale
BCAR1 wt Allele
Design
Case
Imaging Genomics
snacks
conception
No Cases Transmission Pattern
Newar Language
tool, nos
CDISC SEND Study Design Terminology
CTNND1 wt Allele
Radiomics
Convergence
Packaging Case
Oncologist
Tension
fertilization
tension
Scientific Equipment
Catenin Delta-1
conception
Oncology
Case Dosing Unit
True Case Status
Tool

---
https://www.has-sante.fr/jcms/p_3487097/fr/columvi-glofitamab-lymphome-diffus-a-grande-cellule-b-ldgcb
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
infusions, intravenous
Antineoplastic Agents, Immunological
lymphoma, large B-Cell, diffuse
Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
glofitamab
evaluation of the transparency committee
glofitamab

---
https://www.has-sante.fr/jcms/p_3486120/fr/tibsovo-ivosidenib-cancer-des-voies-biliaires
2024
false
false
false
France
locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation
adult
treatment outcome
insurance, health, reimbursement
cholangiocarcinoma
Locally Advanced Cholangiocarcinoma
Metastatic Cholangiocarcinoma
administration, oral
antineoplastic agents
ivosidenib
evaluation of the transparency committee
ivosidenib

---
https://www.has-sante.fr/jcms/p_3471037/fr/
2024
France
health technology assessment
genome, nos
Early Stage Breast Carcinoma
breast cancer
Useful
hospitals, proprietary
Clinical Data
Signature
Genome
early
Clinical Lot
breast neoplasms
Ambulatory Care Facility
neoplasm staging
genomics
Clinical Batch
genome
neoplasm, malignant

---
https://www.has-sante.fr/jcms/p_3487181/fr/optune
2024
France
health technology assessment
antimitotic agents
electric field
Antimitotic Agent
NovoTTF-100A Device
family characteristics
Data Field
ARID1A wt Allele
Electricity
generations
In the Field
Generator Dosing Unit
Generator Device
Scope
Generator

---
https://www.has-sante.fr/jcms/p_3478093/fr/blincyto-blinatumomab-lal-en-echec-d-au-moins-2-traitements-avec-itk
2024
false
false
false
France
precursor cell lymphoblastic Leukemia-Lymphoma
leukemia, lymphocytic, acute, L2
B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1
antineoplastic agents
blinatumomab
evaluation of the transparency committee
blinatumomab

---
https://www.has-sante.fr/jcms/p_3488172/fr/lynparza-olaparib-cancer-de-l-ovaire
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
olaparib
antineoplastic combined chemotherapy protocols
Bevacizumab/Olaparib Regimen
adult
Carcinoma, Ovarian Epithelial
Stage III Ovarian Cancer AJCC v6 and v7
Stage IV Ovarian Cancer AJCC v6 and v7
fallopian tube neoplasms
peritoneal neoplasms
administration, oral
evaluation of the transparency committee
olaparib

---
https://www.has-sante.fr/jcms/p_3487169/fr/tagrisso-osimertinib-cancer-bronchique-non-a-petites-cellules-cbnpc
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
bronchial neoplasms
administration, oral
antineoplastic agents
osimertinib
adult
evaluation of the transparency committee
carcinoma, non-small-cell lung
osimertinib

---
https://ansm.sante.fr/tableau-marr/elranatamab
2024
false
false
false
France
French
risk management
Elranatamab
drug information
patients guideline
Cytokine Release Syndrome
nervous system diseases
elranatamab

---
https://ansm.sante.fr/informations-de-securite/adagrasib-risque-potentiel-deffets-indesirables-cutanes-severes
2024
false
false
false
France
French
pharmacovigilance note
risk
adagrasib
stevens-johnson syndrome
epidermal necrolysis, toxic
adagrasib
antineoplastic agents
Adagrasib Regimen

---
https://www.has-sante.fr/jcms/p_3488409/fr/libtayo-cemiplimab-cancer-bronchopulmonaire-non-a-petites-cellules-cbnpc
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
infusions, intravenous
Antineoplastic Agents, Immunological
cemiplimab
antibodies, monoclonal, humanized
antineoplastic combined chemotherapy protocols
adult
platinum compounds
PD-L1 Positive
evaluation of the transparency committee
carcinoma, non-small-cell lung
cemiplimab

---
https://www.has-sante.fr/jcms/p_3488415/fr/jemperli-dostarlimab-cancer-de-l-endometre
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
infusions, intravenous
dostarlimab
adult
mismatch repair deficient/microsatellite instability-high recurrent or advanced endometrial cancer that has progressed
Advanced Endometrial Carcinoma
Recurrent Endometrial Carcinoma
evaluation of the transparency committee
endometrial neoplasms
dostarlimab

---
https://www.has-sante.fr/jcms/p_3490351/fr/lytgobi-futibatinib-cholangiocarcinome
2024
false
false
false
France
futibatinib
treatment outcome
insurance, health, reimbursement
adult
Intrahepatic Cholangiocarcinoma
antineoplastic agents
Locally Advanced Intrahepatic Cholangiocarcinoma
Metastatic Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma
FGFR2 Gene Rearrangement
FGFR2 Gene Fusion Positive
Cancer Progression
administration, oral
evaluation of the transparency committee
cholangiocarcinoma
futibatinib

---
https://www.has-sante.fr/jcms/p_3490834/fr/trodelvy-sacituzumab-govitecan-cancer-du-sein
2024
false
false
false
France
adult
treatment outcome
insurance, health, reimbursement
infusions, intravenous
sacituzumab govitecan
HER2/Neu Negative
Hormone Receptor Positive
evaluation of the transparency committee
breast neoplasms
sacituzumab govitecan

---
https://www.has-sante.fr/jcms/p_3490820/fr/opdualag-nivolumab/relatlimab-melanome
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
drug combinations
relatlimab
nivolumab and relatlimab
Nivolumab
Antineoplastic Agents, Immunological
infusions, intravenous
Unresectable Cutaneous Melanoma
adult
adolescent
PD-L1 Expression Less than 1 Percent
Advanced Cutaneous Melanoma
evaluation of the transparency committee
melanoma

---
https://assurance-maladie.ameli.fr/etudes-et-donnees/2024-vedolizumab-ustekinumab-anti-tnf-grossesse-mici
2024
France
scientific and technical information
safety
TNF Gene
Ustekinumab
inflammatory bowel disease, nos
tumor necrosis factor
Institutional Review Board Independent Ethics Committee Notification of Safety Information Documentation
Physically Feel in Bad Condition
tumor necrosis factors
Safety Report
Clinical Trial Notification of Safety or Other Trial Information Documentation
chronic disease, nos
Vedolizumab
research report
vedolizumab
disease
Tumor Necrosis Factor
anti-TNF
Ustekinumab
Chronic Disease
Pregnant People
inflammatory bowel diseases
vedolizumab
pregnancy, nos
albumin/globulin ratio
chronic disease
Gravida

---
https://www.calameo.com/onco-occitanie/read/0071780925791d9acadba?language=fr&page=1
2024
France
scientific and technical information
cancer
neoplasms
Pregnant
pregnancy, nos
neoplasm, malignant
Occupational Malignant Neoplasm
pregnancy
Pregnancy
occupational neoplasms

---
https://ansm.sante.fr/tableau-acces-derogatoire/mabthera-100-mg-solution-a-diluer-pour-perfusion
2024
false
false
false
France
French
infusions, intravenous
Product containing precisely rituximab 10 milligram/1 milliliter conventional release solution for infusion (clinical drug)
Rituximab
drug information
guidelines for drug use
Refractory immune thrombocytopenic purpura
purpura, thrombocytopenic, idiopathic
immunologic factors
technical report

---
https://ansm.sante.fr/tableau-marr/etanercept-1
2024
false
false
false
France
French
risk management
Etanercept
patients guideline
drug information
Drug-Related side effects and adverse reactions

---
https://ansm.sante.fr/tableau-marr/rituximab-3
2024
false
false
false
France
French
guidelines for drug use
patient education handout
Rituximab
Rituximab
risk management
continuity of patient care
child
infusions, intravenous
leukoencephalopathy, progressive multifocal
Drug-Related side effects and adverse reactions

---
https://www.has-sante.fr/jcms/p_3425618/fr/voraxaze-glucarpidase-intoxication-au-methotrexate
2024
false
false
false
France
package leaflet
summary of product characteristics
protective agents
glucarpidase
Detoxification
methotrexate
Methotrexate toxicity
methotrexate
evaluation of the transparency committee
glucarpidase

---
https://ansm.sante.fr/tableau-acces-derogatoire/voraxaze-1000-u-poudre-pour-solution-pour-perfusion
2024
false
false
false
France
French
glucarpidase
drug information

---
https://www.has-sante.fr/jcms/p_3443053/fr/enhertu-trastuzumab-deruxtecan-cancer-du-sein-her2
2024
false
false
false
France
adult
treatment outcome
insurance, health, reimbursement
Unresectable HER2-Positive Breast Carcinoma
Metastatic HER2-Positive Breast Carcinoma
neoplasm metastasis
trastuzumab deruxtecan
guidelines for drug use
Antineoplastic Agents, Immunological
infusions, intravenous
evaluation of the transparency committee
breast neoplasms
trastuzumab deruxtecan
Trastuzumab

---
https://www.has-sante.fr/jcms/p_3412521/fr/abecma-idecabtagene-vicleucel-myelome-multiple
https://www.has-sante.fr/jcms/p_3412521/en/abecma-idecabtagene-vicleucel-myelome-multiple
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
Recurrent Multiple Myeloma
Refractory Multiple Myeloma
idecabtagene vicleucel
infusions, intravenous
Antineoplastic Agents, Immunological
evaluation of the transparency committee
idecabtagene vicleucel
multiple myeloma

---
https://ansm.sante.fr/tableau-acces-derogatoire/tecartus-0-4-2-x-108-cellules-dispersion-pour-perfusion
2024
false
false
false
France
French
brexucabtagene autoleucel
drug information
Refractory B Acute Lymphoblastic Leukemia
precursor cell lymphoblastic Leukemia-Lymphoma
brexucabtagene autoleucel
gene therapy

---
https://ansm.sante.fr/tableau-acces-derogatoire/keytruda-25-mg-ml-solution-a-diluer-pour-perfusion#
2024
false
false
false
France
French
drug information
triple negative breast neoplasms
pembrolizumab
pembrolizumab
guidelines for drug use
adult
Early Stage Triple-Negative Breast Carcinoma
Locally Advanced Triple-Negative Breast Carcinoma
inflammatory breast neoplasms
Antineoplastic Agents, Immunological
endometrial neoplasms
clear cell renal cell carcinoma
renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions
antineoplastic combined chemotherapy protocols
Enfortumab Vedotin/Pembrolizumab Regimen
Unresectable Urothelial Carcinoma
Metastatic Urothelial Carcinoma
urologic neoplasms
carcinoma

---
https://www.has-sante.fr/jcms/p_3418585/fr/yescarta-axicabtagene-ciloleucel-lymphome-ldgcb-lhgcb
2024
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
insurance, health, reimbursement
treatment outcome
Recurrent High Grade B-Cell Lymphoma
lymphoma, large B-Cell, diffuse
Refractory High Grade B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
adult
infusions, intravenous
gene therapy
axicabtagene ciloleucel

---
https://ansm.sante.fr/tableau-acces-derogatoire/scemblix-20-mg-40-mg-comprimes-pellicules
2024
false
false
false
France
French
asciminib
administration, oral
guidelines for drug use
asciminib
protein kinase inhibitors
summary of product characteristics
package leaflet
leukemia, lymphocytic, acute, L2
leukemia, lymphocytic, acute, L2
mutation
T315I mutation
leukemia, myelogenous, chronic, bcr-abl positive
leukemia, myelogenous, chronic, bcr-abl positive

---
https://ansm.sante.fr/tableau-acces-derogatoire/breyanzi
2024
false
false
false
France
French
Lisocabtagene Maraleucel
Product containing only lisocabtagene maraleucel in parenteral dose form (medicinal product form)
summary of product characteristics
package leaflet
guidelines for drug use
lymphoma, large B-Cell, diffuse
adult
Recurrent High Grade B-Cell Lymphoma
Refractory High Grade B-Cell Lymphoma
Recurrent Primary Mediastinal Large B-Cell Lymphoma
Refractory Primary Mediastinal Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
infusions, intravenous
continuity of patient care
immunotherapy, adoptive
antigens, CD19
lisocabtagene maraleucel

---
https://ansm.sante.fr/tableau-acces-derogatoire/lynparza-100-mg-et-150-mg-comprimes-pellicules
2024
false
false
false
France
French
drug information
olaparib
administration, oral
olaparib
breast neoplasms
HER2-Negative Breast Carcinoma

---
https://ansm.sante.fr/tableau-marr/teclistamab
2024
false
false
false
France
French
popular works
drug information
Teclistamab
risk management
teclistamab

---
https://ansm.sante.fr/tableau-acces-derogatoire/adcetris-50-mg-poudre-pour-solution-a-diluer-pour-perfusion
2024
false
false
false
France
French
continuity of patient care
guideline
hodgkin disease
child
adolescent
adult
antineoplastic combined chemotherapy protocols
brentuximab vedotin
Brentuximab Vedotin
infusions, intravenous

---
https://ansm.sante.fr/tableau-marr/cemiplimab
2024
false
false
false
France
French
risk management
patients guideline
cemiplimab
Antineoplastic Agents, Immunological
infusions, intravenous
cemiplimab
drug monitoring
lymphohistiocytosis, hemophagocytic
drug information
lymphohistiocytosis, hemophagocytic

---
https://ansm.sante.fr/tableau-marr/axicabtagene-ciloleucel
2024
false
false
false
France
French
risk management
axicabtagene ciloleucel
guidelines for drug use
axicabtagene ciloleucel
Drug-Related side effects and adverse reactions
Cytokine Release Syndrome
nervous system diseases
patient education handout
signs and symptoms
axicabtagene ciloleucel
infusions, intravenous
gene therapy

---
https://ansm.sante.fr/tableau-marr/brexucabtagene-autoleucel
2024
false
false
false
France
French
risk management
brexucabtagene autoleucel
genetic therapy
gene therapy
Cytokine Release Syndrome
signs and symptoms
guidelines for drug use
patient education handout
Drug-Related side effects and adverse reactions
nervous system diseases
brexucabtagene autoleucel
brexucabtagene autoleucel

---
https://ansm.sante.fr/tableau-marr/venetoclax
2024
false
false
false
France
French
risk management
venetoclax
venetoclax
patient education handout
tumor lysis syndrome
administration, oral
antineoplastic agents

---
https://ansm.sante.fr/tableau-marr/panobinostat
2024
false
false
false
France
French
risk management
Panobinostat
panobinostat
administration, oral
medication errors
patients guideline
patient compliance

---
Nous contacter.
14/07/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.